Services
Individual researchers or consortia applying for international or national grants and aiming to screen for chemical tools to unravel their basic research questions are invited to contact EU-OPENSCREEN for support.
We will support you on the screening part of your application and enable you to file a strong research case. This can be achieved, e.g. by providing you help in writing, identifying potential gaps and bottlenecks that can be experienced during the project’s execution, or by enabling you to perform a pilot screen to test your assay.
We can help you to identify the right partner for your consortium among EU-OPENSCREEN Chemical Biology sites.
ISIDORe launched its first calls for transnational access for projects to study SARS-CoV-2 and other pathogens. You can access EU-OPENSCREEN's screening and chemistry partner sites offering drug discovery and early preclinical development services to external researchers in academia and industry working on new therapeutics against SARS-CoV-2 variants and epidemic-prone pathogens.
Activities range from
Moreover, EU-OPENSCREEN teams up with European partners that offer access to
What kind of funding is available?
How do I apply?
What else?
More information on the calls can be found on the ISIDORe website.
The EU-OPENSCREEN DRIVE project is funded under the European Union´s research and innovation programme Horizon 2020 ensuring long-term sustainability of excellence in chemical biology within Europe and provides researchers with access to cutting-edge European small molecule screening, medicinal chemistry and chemoproteomics facilities. EU-OPENSCREEN ERIC central office is responsible for the management of the transnational access calls.
Within this project EU-OPENSCREEN is offering 23 fully funded research projects in the areas of chemoproteomics, small molecule screening and medicinal chemistry. Eligible proposals will be evaluated by external reviewers, and successful applicants will be selected in an open and transparent process.Transnational access comprises a total of 6 chemoproteomics, 12 small molecule screening and 5 medicinal chemistry projects. The European Commission only allows transnational access, meaning that users are not eligible to get access to a facility that is located in their home country.
For more information please visit the DRIVE project website.